Email updates

Keep up to date with the latest news and content from BMC Neurology and BioMed Central.

Open Access Research article

Treatment of neuromyelitis optica/neuromyelitis optica spectrum disorders with methotrexate

Ramnath Santosh Ramanathan*, Konark Malhotra and Thomas Scott

Author Affiliations

Department of Neurology, Drexel University College of Medicine, Allegheny General Hospital, 4742 Centre Avenue, Apt 703, Pittsburgh, PA 15213, USA

For all author emails, please log on.

BMC Neurology 2014, 14:51  doi:10.1186/1471-2377-14-51

Published: 15 March 2014

Abstract

Background

To review our experience using methotrexate as a single long-term immunosuppressant (IS) therapy in neuromyelitis optica/neuromyelitis optica spectrum disorders (NMO/NMOSD).

Methods

We performed a retrospective chart review of all patients with a diagnosis of NMO/NMOSD, supported by a positive NMO-IgG testing, who were treated with methotrexate. A paired sample 2 tailed t test was used to assess the annualized relapse rate during 18 months pre treatment with methotrexate to annualized relapse rate 18 months post treatment with methotrexate.

Results

We followed 9 patients meeting criteria for the study for a median of 62 months. All patients were stabilized during attacks with high-dose steroids and/or plasmapheresis. Five patients (55.55%) were started on methotrexate as an initial long-term immunosuppressant strategy. Three patients (33.33%) were initially treated with pulse cyclophosphamide followed by methotrexate as a preplanned step-down strategy. One patient was started on azathioprine prior to methotrexate. No patient had side effects requiring change in methotrexate therapy. Five patients (55.55%) had stabilization of Expanded Disability Status Scale (EDSS) on methotrexate. One patient had a small increase in EDSS due to concomitant illness. Three patients (33.33%) had methotrexate treatment failure evidenced by worsening EDSS and ongoing relapses while on methotrexate, mandating a change in methotrexate therapy. Average annualized relapse rate in the entire group comparing 18 months prior versus 18 months after methotrexate treatment was reduced by an absolute value of 64% (3.11 vs 1.11). A paired t-test showed this reduction was highly significant (pā€‰=ā€‰.009).

Conclusion

In our experience, methotrexate is safe and possibly efficacious as a single long-term IS therapy along with low dose corticosteroids that can reasonably be offered to patients with NMO/NMOSD.

Keywords:
Neuromyelitis optica; Neuromyelitis optica spectrum disorders; Methotrexate; Immunosuppressant therapy